BOLT Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. (BOLT) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $2.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.4% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.